Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Mustang Bio, Inc. (NASDAQ: MBIO) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel cell and gene therapies. Their primary focus is on translating medical breakthroughs into potential cures for hard-to-treat hematologic cancers, solid tumors, and rare genetic diseases. Mustang Bio's pipeline includes CAR T cell therapies and in vivo gene therapies, supported by their integrated research, development, and cGMP manufacturing capabilities in Worcester, MA.
Corporate headquarters, research and development laboratories, and a state-of-the-art cGMP-compliant cell therapy manufacturing facility.
Integrated, cGMP-compliant manufacturing facility for clinical supply of both CAR T and viral vector products, enabling end-to-end research, development, and manufacturing capabilities on-site.
A dynamic, science-driven environment focused on innovation, collaboration, and a strong commitment to patients. The culture emphasizes scientific rigor and urgency in developing potentially curative therapies.
The Worcester headquarters and manufacturing facility is strategically located within a biotechnology hub (UMass Medicine Science Park), providing access to talent and resources. The integrated nature of the facility allows for streamlined development and production of complex cell and gene therapies.
Mustang Bio's primary operations, including research, development, and manufacturing, are centralized in the United States at their Worcester, MA facility. While their physical footprint is U.S.-based, the company's clinical trials may involve sites globally, and they explore international partnerships for the development and commercialization of their therapies. Their work aims to address diseases affecting patients worldwide.
377 Plantation Street
Worcester
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Mustang Bio' leadership includes:
Mustang Bio has been backed by several prominent investors over the years, including:
In the past 12-18 months, Mustang Bio saw a change in the Chief Medical Officer role, with an appointment in May 2023 and a subsequent resignation in February 2024. The company is currently without a publicly listed Chief Medical Officer on its leadership team page.
Discover the tools Mustang Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Mustang Bio likely utilizes common corporate email formats. Based on industry patterns, the most probable format involves a combination of the employee's first initial and last name.
[firstinitial][last]@mustangbio.com
Format
jdoe@mustangbio.com
Example
90%
Success rate
GlobeNewswire • May 15, 2024
Mustang Bio announced its financial results for the first quarter ending March 31, 2024, and provided updates on its clinical programs, including progress with MB-106 (CD20-targeted CAR T) and MB-207 (XSCID gene therapy)....more
GlobeNewswire • April 2, 2024
Mustang Bio highlighted the publication of preclinical data supporting the potential of its MB-207 lentiviral gene therapy, administered in utero, for X-linked severe combined immunodeficiency (XSCID)....more
GlobeNewswire • February 13, 2024
The company announced the dosing of the first patient in the B-cell non-Hodgkin lymphoma cohort of its pivotal Phase 2 clinical trial for MB-106, a CD20-targeted autologous CAR T cell therapy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Mustang Bio, are just a search away.